The effect of lipopolysaccharide (LPS) on the production of fibrinolytic inhibitor by human endothelial cells was determined because results of previous experiments have shown us that it is possible to stimulate this synthesis with muramyl dipeptide. Treatment of these cells with LPS resulted in a marked enhancement of fibrinolytic inhibitor, as estimated in a urokinase-induced fibrinolysis assay. A dose-response curve was obtained for LPS concentrations ranging from 10 to 1,000 ng/ml, thus demonstrating the great sensitivity of these cells. This inhibitor did not reduce plasmin activity and formed complexes with high-and low-molecularweight urokinase as visualized by fibrin enzymography on sodium dodecyl sulfate-polyacrylamide electrophoretic gels. The molecular weight of this inhibitor was estimated to be 54 to 58 kilodaltons. These (16) . In this study we examine the effects of lipopolysaccharide (LPS) on the production of fibrinolytic inhibitor by cultured human endothelial cells. The ability of these cells to synthesize inhibitor(s) of plasminogen activators has been demonstrated previously (7, 10, 12, 22, 28) . Recently, we have observed that muramyl dipeptide (MDP), the immunoadjuvant properties of which have been well documented (3, 20) , could stimulate this fibrinolytic inhibitor synthesis (6). This led us to compare the sensitivity of the endothelial response toward LPS and MDP. It has been described previously that LPS reduces the production of plasminogen activator by macrophages in vitro (1, 9). The involvement of an inhibitor was not demonstrated in vitro (9), although fibrinolytic inhibitory activity was found in vivo in the ascite liquid following endotoxin injection (2). This led us to determine whether LPS might increase fibrinolytic inhibitor production by human endothelial cells. The data obtained from this study provide evidence that LPS induces the generation of a plasminogen antiactivator. Inhibition of urokinase-induced fibrinolysis. Supernatants were mixed (1: 1, vol/vol) with 6 to:Z5 U of urokinase solution (Institut Choay, Paris, France)'per ml, and 30 ,ul of the mixture was deposited on a standard fibrin plate prepared with rich plasminogen bovine fibrinogen (Koch and Light Laboratories, Colnbrook, England) as described previously (6). The lysis area was measured after 18 h at 37°C. Results were expressed as the inhibition percentage of the lysis area induced by urokinase mixed with unconditioned medium.
Microvascular alterations in response to in vivo administration of endotoxin have been recognized for a long time and have been shown to involve leukocyte adherence, platelet aggregation, and activation of several steps of coagulation that lead to vascular obstruction (25) . Direct effects of endotoxin on vascular endothelium also have been described, such as injury of bovine endothelial cells (16, 31) , induction of thromboplastin (13) , and colony-stimulating factor synthesis (29) in human cells. However, neither cytotoxicity nor modifications in synthesis of factor VIII antigen, angiotensin-converting enzyme, and prostacyclin release were found when human cells were used (16) . In this study we examine the effects of lipopolysaccharide (LPS) on the production of fibrinolytic inhibitor by cultured human endothelial cells. The ability of these cells to synthesize inhibitor(s) of plasminogen activators has been demonstrated previously (7, 10, 12, 22, 28) . Recently, we have observed that muramyl dipeptide (MDP), the immunoadjuvant properties of which have been well documented (3, 20) , could stimulate this fibrinolytic inhibitor synthesis (6) . This led us to compare the sensitivity of the endothelial response toward LPS and MDP. It has been described previously that LPS reduces the production of plasminogen activator by macrophages in vitro (1, 9) . The involvement of an inhibitor was not demonstrated in vitro (9) , although fibrinolytic inhibitory activity was found in vivo in the ascite liquid following endotoxin injection (2) . This led us to determine whether LPS might increase fibrinolytic inhibitor production by human Inhibition of urokinase-induced fibrinolysis. Supernatants were mixed (1: 1, vol/vol) with 6 to:Z5 U of urokinase solution (Institut Choay, Paris, France)'per ml, and 30 ,ul of the mixture was deposited on a standard fibrin plate prepared with rich plasminogen bovine fibrinogen (Koch and Light Laboratories, Colnbrook, England) as described previously (6) . The (1:1, vol/vol) with 50 VI of 6 U of urokinase per ml for 2 and then supplemented with 100 ,ul of SDS sample b giving a final SDS concentration of 2.5%. A total of 10( this mixture was applied to a 10% acrylamide gel for trophoresis at a constant current of 80 mA for 2.40 h. T was washed by the original method and placed on; agarose-fibrin gel which was prepared as follows. A tc 1.8 ml of 2% indubiose (kept at 44°C) was mixed with: of 0.2 U of thrombin (kept at 44°C) per ml and 1.7 ml mg of bovine fibrinogen per ml that was rich in plasmi (kept at 37°C). The higher molecular weight bands were also present. This provides evidence that the cell supernatant contains a component that is bound to the two molecular species of urokinase, leading to the formation of higher molecular weight complexes. These modifications were more important after treatment of the cells with LPS. Effect of polymyxin B and E (colimycin) on LPS-induced fibrinolytic inhibition. Polymyxin B has been shown to block several LPS effects (5, 18, 23, 27, 30, 33) , probably by binding to the lipid A moiety (24) . Therefore, we tested the ability of this antibiotic at various concentrations (8 to 400 U/ml, i.e., 1 to 50 ,ug/ml) to suppress the urokinase fibrinolytic inhibition induced by 1 ,ug of LPS per ml (Fig.  3A) . At 8 U/ml the effect of LPS was greatly reduced, and maximum suppression occurred with 80 U of polymyxin B per ml. In the following experiments 160 U/ml was used because polymyxin B has no direct effect on the cells or on the fibrinolytic reaction, even at 400 U/ml. Complementary experiments Were performed, with a constant concentration of polymyxin B (160 U/ml) being added to increasing amounts of LPS. This polymyxin B concentration was able to neutralize entirely the effect of 0.5 ,ug of LPS per ml but not of 5 or 10 ,ug/ml. Polymyxin E or colimycin was also tested in this model (Fig. 3B) . Colimycin also neutralized the effect of LPS, although less efficiehtly than did polymyxin B. LPS (1 ,ug/ml) incubated alone with endothelial cells produced a 100% inhibition of 6 U of urokinase per ml. Simultaneous treatment with colimycin led to a dose-dependent suppression of the LPS-induced inhibition, and total blockage was observed with 400 U of colimycin per ml. Incubation with colimycin alone did not change the basal inhibitory activity, Effect of polymyxin B on MDP-induced fibrinolytic inhibition. As described previously (6) , MDP also stimulates the synthesis of fibrinolytic inhibitor in cultured endothelial cells. The susceptibility of this MDP effect to polymnyxin B therefore was determined (Table 2) . Incubation with MDP (10 to 100 ,ug/ml) produced a dose-dependent inhibition of urokinase fibrinolytic inhibition. However, it was necessary to use at least 1,000 times more MDP than LPS to induce a similar inhibition. A 100% inhibition of 6 U of urokinase per a Cells were treated with MDP in the absence or presence of polymyxin B (160 U/ml = 20 ,ug/ml), and the supernatant was tested against 6 U of urokinase per nil. Valves are means ± standard deviations of two different experiments.
ml generally required treatment of 50 ,ug of MDP per ml instead of 0.05 ,ug of LPS per ml. This MDP response was not reduced by polymyxin B (160 U/ml).
Protein synthesis in the cells exposed to the compounds used in this study was verified by the cell incorporation of before SDS-PAGE. This gel was applied for 5 h on a fibrin agarose revelator gel. Clear bands correspond to fibrinolysis due to the transfer of enzymatic activity from the electrophoretic gel. (6) . Under these conditions LPS had no visible effect, but substitution of clinically injectable nonpyrogenic human albumin allowed detection of a clear stimulating activity of LPS. This led us to think that contamination of bovine albumin by an endotoxin might explain the lack of cell response to additional LPS. This was further supported by the fact that polymyxin B addition to untreated endothelial cells incubated in bovine albumin decreases the basal level of fibrinolytic inhibitor (unpublished data).
Results of this study, performed with an incubation medium containing nonpyrogenic human albumin, demonstrate that LPS (10 ng to 10 ,ug per ml) strongly stimulates production of a factor that inhibits urokinase-induced fibrinolysis. Because plasmin activity was not modified, this argues against the presence of an antiplasmin. Results of SDS-PAGE and fibrin enzymography provide evidence for the implication of a supernatant component which decreases the activity of 35-and 53-kDa urokinase and forms complexes of 93 and 107 kDa. From these results it can be calculated that the urokinase-binding factor has a molecular mass of 54 to 58 kDa. This is in agreement with data reported by others (28, 32) . LPS treatment stimulated the formation of such a urokinase-binding factor, resulting in a further reduction of the two lysis bands of urokinase.
The complexes of high molecular weight retained their catalytic activity after SDS-PAGE. Similar observations on protease-antiprotease complex activity separated in the presence of SDS have been carried out previously (15, 28) . It has been proposed that SDS induces changes in the structure of the protease-antiprotease complex so that its catalytic site is exposed (15, 21) .
It has been shown that endothelial cell supernatant also forms a complex with melanoma plasminogen activator (28, 32) and inhibits fibrinolytic activity from venostatis human plasma (6) . This suggests that the plasminogen antiactivator formed by endothelial cells might interfere with tumoral cell plasminogen activator, thrombolytic therapy, and physiological hyperfibrinolytic reactions.
The induction of plasminogen antiactivator by LPS could be suppressed by polymyxin B. This cationic antibiotic was shown to form a complex with the lipid A part of the LPS molecule (24) , and it could be proposed that this lipid moiety is involved in the LPS-endothelial interaction. It was found that 160 U of polymyxin B per ml (20 ,ug/ml) neutralized 0.5 to 1 jig of LPS per ml, but this was not sufficient to abolish the effect of higher LPS concentrations. When expressed on a weight basis, the requirement of polymyxin B for neutralizing LPS in our model appeared greater than was reported by other investigators, who used a different experimental system (9, 33) . This might be due to the fact that polymyxin B also has a great affinity for phospholipids (5) and interacts with enzymes that contain a phospholipid-binding domain (26) .
The finding that colimycin had the same effect as polymyxin B might be expected from their structural similarities. This is of interest with regard to clinical use of colimycin. The amounts of colimycin used in this study are compatible with the concentration reached in blood after intravenous administration. Therefore, colimycin, in addition to its bactericidal activity, might have a potential advantage during endotoxemia for preventing endotoxininduced reduction of the fibrinolytic capacity.
Plasminogen antiactivator was detected in blood after experimental endotoxin injection or in patients with septicemia (4). These findings underline the clinical relevance of such LPS-induced generation of antifibrinolytic component(s) which might originate from endothelium but also, perhaps, from monocytes (14) and platelets (11) .
